Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Revive Therapeutics Ltd (RVVTF)

Revive Therapeutics Ltd (RVVTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke GlobeNewswire - Tue Nov 12, 6:45AM CST

RVV.CN : 0.0050 (-50.00%)
RVVTF : 0.0063 (+1.61%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure GlobeNewswire - Thu Oct 31, 6:30AM CDT

RVV.CN : 0.0050 (-50.00%)
RVVTF : 0.0063 (+1.61%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Globe Newswire - Mon Jul 25, 2022

TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Globe Newswire - Fri Jun 24, 2022

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Globe Newswire - Mon Jun 6, 2022

The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Globe Newswire - Thu May 26, 2022

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Globe Newswire - Mon May 16, 2022

The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Globe Newswire - Mon Apr 25, 2022

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19 Globe Newswire - Mon Apr 18, 2022

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Globe Newswire - Mon Apr 11, 2022

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.0063 (+1.61%)
RVV.CN : 0.0050 (-50.00%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot